Total Raised
$50.8MInvestors Count
5Deal Terms
3Funding, Valuation & Revenue
5 Fundings
TARIS Biomedical - LiRIS has raised $50.8M over 5 rounds.
TARIS Biomedical - LiRIS's latest funding round was a Acquired Unit for on August 13, 2014.
TARIS Biomedical - LiRIS's latest post-money valuation is from August 2014.
Sign up for a free demo to see TARIS Biomedical - LiRIS's valuations in August 2014 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
8/13/2014 | Acquired Unit | 1 | ||||
4/2/2013 | Series C | |||||
4/13/2011 | Series B - II | |||||
12/14/2009 | Series B | |||||
8/5/2008 | Series A |
Date | 8/13/2014 | 4/2/2013 | 4/13/2011 | 12/14/2009 | 8/5/2008 |
|---|---|---|---|---|---|
Round | Acquired Unit | Series C | Series B - II | Series B | Series A |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
TARIS Biomedical - LiRIS Deal Terms
3 Deal Terms
TARIS Biomedical - LiRIS's deal structure is available for 3 funding rounds, including their Acquired Unit from August 13, 2014.
Round | Acquired Unit | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired Unit | |||||||||||||||
Series B | |||||||||||||||
Series A |
TARIS Biomedical - LiRIS Investors
5 Investors
TARIS Biomedical - LiRIS has 5 investors. Allergan (acquired by Actavis) invested in TARIS Biomedical - LiRIS's Acquired Unit funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/13/2014 | 8/13/2014 | 1 Acquired Unit | Corporation | California | ||
Venture Capital | New York | |||||
Venture Capital | Massachusetts | |||||
Venture Capital | Massachusetts | |||||
Venture Capital | Massachusetts |
First funding | 8/13/2014 | ||||
|---|---|---|---|---|---|
Last Funding | 8/13/2014 | ||||
Investor | |||||
Rounds | 1 Acquired Unit | ||||
Board Seats | |||||
Type | Corporation | Venture Capital | Venture Capital | Venture Capital | Venture Capital |
Location | California | New York | Massachusetts | Massachusetts | Massachusetts |
Compare TARIS Biomedical - LiRIS to Competitors
Intarcia Therapeutics is a biotech company that focuses on the development of biologics and peptides for the treatment of cardio-renal-metabolic diseases. The company's main offerings include a pipeline of long-acting GLP-1 receptor agonists and other peptide-based therapies designed to improve the management of chronic diseases. Intarcia primarily serves sectors in the healthcare industry that are involved with chronic disease management and biopharmaceuticals. It was founded in 1995 and is based in Boston, Massachusetts.
Cosmo S.p.A. is a company operating in health technology within the medical sector. It offers products and services that utilize science and artificial intelligence to assist healthcare professionals in areas including dermatology, gastroenterology, and contract development and manufacturing. It is based in Italy.
Orexo is a pharmaceutical company that focuses on the development of improved pharmaceuticals. The company's main offerings include innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Orexo primarily sells to the healthcare industry. It is based in Uppsala, Sweden.
Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.
CoImmune is involved in the development and manufacture of cell-based therapeutics within the healthcare sector. The company works on treatments for cancer, autoimmune, and inflammatory diseases. Its clientele includes sectors seeking medical therapies for complex conditions. CoImmune was formerly known as Argos Therapeutics. It was founded in 1997 and is based in Durham, North Carolina. CoImmune operates as a subsidiary of Genexine and SCM Lifescience.
Traversa Therapeutics is a company that operates in the healthcare sector, with a focus on developing therapeutic treatments. The company's main offerings include the development and provision of various therapeutic treatments designed to address different health conditions. It was founded in 2006 and is based in La Jolla, California.
Loading...